Zota Health Care Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 21, 2024, 1:35 am

Market Cap	2,148 Cr.
Current Price	784
High / Low	822/440
Stock P/E
Book Value	58.0
Dividend Yield	0.13 %
ROCE	7.32 %
ROE	16.8 %
Face Value	10.0
PEG Ratio	0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for

Competitors of

Stock Name	Market Cap	Current Price	High / Low	Stock P/E	Book Value	Dividend Yield	ROCE	ROE	Face Value
Gujarat Themis Biosyn Ltd	3,354 Cr.	308	390/128	63.6	20.5	0.22 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	62.6 Cr.	84.4	94.9/26.6	24.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	35.9 Cr.	24.5	24.5/8.74	46.6	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	86.7 Cr.	115	155/87.0	13.0	55.4	0.00 %	14.4 %	15.5 %	10.0
Glenmark Life Sciences Ltd	12,416 Cr.	1,013	1,335/645	29.3	207	2.22 %	28.1 %	21.1 %	2.00
Industry Average	14,994.84	N/A		46.07	N/A	N/A	16.07	15.77	N/A

All Competitor Stocks of

Quarterly Result

Month	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Sales	33	35	31	31	29	39	35	37	39	45	47	50	56
Expenses	29	31	26	31	28	34	35	36	37	41	44	51	58
Operating Profit	5	5	5	0	1	5	0	1	1	4	3	-1	-1
OPM %	15%	14%	16%	0%	5%	12%	0%	3%	3%	10%	7%	-3%	-2%
Other Income	0	0	0	1	0	1	1	1	0	0	0	0	0
Interest	0	0	0	0	0	1	1	1	1	1	1	2	3
Depreciation	1	1	1	2	2	3	3	4	3	5	5	7	8
Profit before tax	5	4	5	-1	-0	2	-3	-3	-3	-1	-3	-10	-12
Tax %	26%	26%	26%	1%	119%	58%	-4%	-15%	1%	49%	7%	-27%	5%
Net Profit	3	3	3	-1	-1	1	-3	-3	-3	-2	-3	-7	-13
EPS in Rs	1.37	1.28	1.33	-0.40	-0.33	0.36	-1.28	-1.05	-1.13	-0.64	-1.14	-2.68	-4.79

Last Updated: October 7, 2024, 8:50 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: September 23, 2024, 3:13 pm

Month	Mar 2011	Mar 2012	Mar 2014	Mar 2015	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	25	38	50	56	85	95	106	131	139	180	198
Expenses	21	33	43	47	77	90	105	116	132	173	193
Operating Profit	4	5	6	8	8	5	1	15	7	8	5
OPM %	14%	13%	13%	15%	9%	5%	1%	11%	5%	4%	3%
Other Income	0	0	0	0	2	2	2	2	2	1	1
Interest	0	1	1	1	0	0	0	0	3	5	7
Depreciation	0	1	1	2	1	2	3	4	12	20	25
Profit before tax	3	3	5	6	8	4	-0	12	-5	-16	-26
Tax %	34%	33%	33%	33%	29%	29%	-41%	28%	23%	-11%
Net Profit	2	2	3	4	6	3	-0	9	-6	-14	-24
EPS in Rs	2.17	1.43	1.85	2.12	2.26	1.12	-0.09	3.54	-2.29	-5.55	-9.25
Dividend Payout %	-0%	50%	38%	34%	32%	90%	-1,170%	42%	-44%	-18%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2011-2012	2014-2015	2019-2020	2020-2021	2022-2023	2023-2024
YoY Net Profit Growth (%)	0.00%	33.33%	-50.00%	-100.00%	-166.67%	-133.33%
Change in YoY Net Profit Growth (%)	0.00%	33.33%	-83.33%	-50.00%	-66.67%	33.33%

has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2011-2012 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	14%
5 Years:	16%
3 Years:	19%
TTM:	41%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	-219%

Stock Price CAGR
10 Years:	%
5 Years:	33%
3 Years:	25%
1 Year:	65%

Return on Equity
10 Years:	%
5 Years:	-3%
3 Years:	-5%
Last Year:	-17%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 2:25 pm

Month	Mar 2011	Mar 2012	Mar 2014	Mar 2015	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	7	10	12	14	18	25	25	25	25	26	27
Reserves	5	3	4	4	51	44	42	64	55	64	132
Borrowings	3	6	5	5	-0	-0	-0	15	45	95	107
Other Liabilities	5	10	14	17	21	20	19	35	33	43	51
Total Liabilities	20	29	35	40	90	88	85	139	158	228	317
Fixed Assets	8	10	9	8	10	15	14	29	62	103	137
CWIP	0	0	-0	-0	2	-0	0	-0	3	5	5
Investments	0	0	0	0	16	14	10	33	8	5	44
Other Assets	12	19	26	32	63	59	61	77	85	116	130
Total Assets	20	29	35	40	90	88	85	139	158	228	317

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	3	5	-3	6	-1	13	-2	-6
Cash from Investing Activity +	-1	-1	9	-4	4	-27	15	-13
Cash from Financing Activity +	-2	-4	-6	-3	-2	14	-14	19
Net Cash Flow	0	0	-1	-1	1	1	-1	-0

Free Cash Flow

Month	Mar 2011	Mar 2012	Mar 2014	Mar 2015	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	1.00	-1.00	1.00	3.00	8.00	5.00	1.00	0.00	-38.00	-87.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2011	Mar 2012	Mar 2014	Mar 2015	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	75	71	79	77	95	112	99	102	73	55
Inventory Days	122	141	134	175	208	139	140	121	183	201
Days Payable	77	90	0	0	104	82	77	78	116	126
Cash Conversion Cycle	120	123	212	251	199	169	161	145	140	131
Working Capital Days	102	89	86	100	175	152	143	115	135	140
ROCE %		20%		32%		6%	-2%	15%	-2%	-7%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	68.09%	68.11%	68.12%	68.12%	68.12%	68.12%	68.12%	66.16%	66.15%	66.15%	64.44%	62.40%
FIIs	0.00%	0.00%	0.00%	0.07%	0.00%	0.00%	0.04%	0.02%	0.00%	0.00%	0.01%	0.01%
DIIs	0.34%	0.30%	0.45%	0.05%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.99%
Public	31.57%	31.59%	31.43%	31.75%	31.88%	31.88%	31.84%	33.83%	33.85%	33.85%	35.55%	36.60%
No. of Shareholders	7,255	7,817	8,149	7,866	7,956	7,233	7,107	7,285	7,589	7,435	7,661	8,937

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	-5.59	-2.29	3.58	-0.09	1.12
Diluted EPS (Rs.)	-5.47	-2.29	3.58	-0.09	1.12
Cash EPS (Rs.)	2.22	2.46	5.00	1.21	1.97
Book Value[Excl.RevalReserv]/Share (Rs.)	34.81	31.94	35.62	26.99	28.02
Book Value[Incl.RevalReserv]/Share (Rs.)	34.81	31.94	35.62	26.99	28.02
Revenue From Operations / Share (Rs.)	69.83	55.63	52.14	43.48	38.73
PBDIT / Share (Rs.)	3.37	3.69	6.53	0.76	2.45
PBIT / Share (Rs.)	-4.40	-1.06	5.07	-0.52	1.60
PBT / Share (Rs.)	-6.25	-1.86	4.94	-0.14	1.57
Net Profit / Share (Rs.)	-5.55	-2.29	3.54	-0.08	1.12
NP After MI And SOA / Share (Rs.)	-5.55	-2.29	3.54	-0.08	1.12
PBDIT Margin (%)	4.82	6.63	12.52	1.76	6.33
PBIT Margin (%)	-6.30	-1.90	9.72	-1.20	4.13
PBT Margin (%)	-8.95	-3.35	9.47	-0.34	4.06
Net Profit Margin (%)	-7.94	-4.12	6.78	-0.19	2.88
NP After MI And SOA Margin (%)	-7.94	-4.12	6.78	-0.19	2.88
Return on Networth / Equity (%)	-15.94	-7.18	9.93	-0.31	3.98
Return on Capital Employeed (%)	-7.35	-2.26	12.36	-1.90	5.62
Return On Assets (%)	-6.28	-3.65	6.40	-0.24	3.09
Total Debt / Equity (X)	0.16	0.00	0.00	0.00	0.00
Asset Turnover Ratio (%)	0.93	0.94	1.25	1.23	1.07
Current Ratio (X)	1.51	2.08	2.14	3.36	3.17
Quick Ratio (X)	0.78	1.05	1.33	1.81	1.80
Inventory Turnover Ratio (X)	0.26	0.49	0.71	0.75	0.45
Dividend Payout Ratio (NP) (%)	-18.01	-65.37	28.24	-1175.68	89.57
Dividend Payout Ratio (CP) (%)	45.05	61.02	20.00	82.97	50.75
Earning Retention Ratio (%)	118.01	165.37	71.76	1275.68	10.43
Cash Earning Retention Ratio (%)	54.95	38.98	80.00	17.03	49.25
Interest Coverage Ratio (X)	1.82	3.62	51.22	17.16	86.87
Interest Coverage Ratio (Post Tax) (X)	-2.00	-1.46	28.78	-10.27	40.51
Enterprise Value (Cr.)	1240.13	707.78	746.47	338.81	319.06
EV / Net Operating Revenue (X)	6.87	5.06	5.69	3.17	3.35
EV / EBITDA (X)	142.37	76.17	45.44	179.81	52.92
MarketCap / Net Operating Revenue (X)	6.80	5.07	5.71	3.19	3.36
Retention Ratios (%)	118.01	165.37	71.75	1275.68	10.42
Price / BV (X)	13.63	8.82	8.35	5.13	4.65
Price / Net Operating Revenue (X)	6.80	5.07	5.71	3.19	3.36
EarningsYield	-0.01	-0.01	0.01	0.00	0.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of as of December 22, 2024 is: 146.35

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 22, 2024, is Overvalued by 81.33% compared to the current share price 784.00

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of as of December 22, 2024 is: 92.05

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 22, 2024, is Overvalued by 88.26% compared to the current share price 784.00

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -37.10%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (42.55 cr) compared to borrowings (25.55 cr), indicating strong financial stability.	The stock has a low average ROCE of 6.20%, which may not be favorable. The stock has a high average Working Capital Days of 123.70, which may not be favorable. The stock has a high average Cash Conversion Cycle of 165.10, which may not be favorable. The company has not shown consistent growth in sales (100.27) and profit (-0.55).

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in :
1. Net Profit Margin: -7.94%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: -7.35% (Industry Average ROCE: 16.07%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: -15.94% (Industry Average ROE: 15.77%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): -2
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.78
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 0 (Industry average Stock P/E: 46.07)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.16
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Zota Healthcare Ltd. is a Public Limited Listed company incorporated on 12/07/2000 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24231GJ2000PLC038352 and registration number is 038352. Currently Company is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company’s Total Operating Revenue is Rs. 131.53 Cr. and Equity Capital is Rs. 25.16 Cr. for the Year ended 31/03/2022.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Zota House, 2/896, Surat Gujarat 395002	info@zotahealthcare.com http://www.zotahealthcare.com

Management
Name	Position Held
Mr. Ketankumar Chandulal Zota	Non Executive Chairman
Mr. Moxesh Ketanbhai Zota	Managing Director
Mr. Kamlesh Rajnikant Zota	Whole Time Director
Mr. Himanshu Muktilal Zota	Whole Time Director
Mr. Viren Manukant Zota	Whole Time Director
Mr. Laxmi Kant Sharma	Executive Director
Mrs. Jaysheeben Nileshkumar Mehta	Ind. Non-Executive Director
Mrs. Bhumi Maulik Doshi	Ind. Non-Executive Director
Dr.(Mrs.) Varsaben Gaurang Mehta	Ind. Non-Executive Director
CA. Dhaval Chandubhai Patwa	Ind. Non-Executive Director
CA. Vitrag Sureshkumar Modi	Ind. Non-Executive Director
Dr. Dhiren Prafulbhai Shah	Ind. Non-Executive Director

FAQ

What is the latest intrinsic value of ?

The latest intrinsic value of as on 22 December 2024 is ₹146.35, which is 81.33% lower than the current market price of ₹784.00. The stock has a market capitalization of 2,148 Cr. and recorded a high/low of 822/440 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹132 Cr and total liabilities of ₹317 Cr.

What is the Market Cap of ?

The Market Cap of is 2,148 Cr..

What is the current Stock Price of as on 22 December 2024?

The current stock price of as on 22 December 2024 is 784.

What is the High / Low of stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of stocks is 822/440.

What is the Stock P/E of ?

The Stock P/E of is .

What is the Book Value of ?

The Book Value of is 58.0.

What is the Dividend Yield of ?

The Dividend Yield of is 0.13 %.

What is the ROCE of ?

The ROCE of is 7.32 %.

What is the ROE of ?

The ROE of is 16.8 %.

What is the Face Value of ?

The Face Value of is 10.0.